Enliven Therapeutics (ELVN) Earnings Analysis

Enliven Therapeutics (ELVN) next reports earnings on 2026-08-12, consensus EPS -0.38 USD. Last quarter (2026-05-07) it beat with EPS -0.38 USD vs -0.44 USD est (+13.6%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -32.23.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ELVN next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.38 USD
Revenue estimaten/a

ELVN earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.38 USD-0.44 USD+13.6%Beat
2026-03-03-0.48 USD-0.42 USD-14.3%Miss
2025-11-12-0.32 USD-0.43 USD+25.6%Beat
2025-08-13-0.49 USD-0.53 USD+7.5%Beat
2025-05-14-0.57 USD-0.51 USD-11.8%Miss
2025-03-13-0.46 USD-0.53 USD+13.2%Beat

Beat rate: 4/6 (67%) over reported quarters with consensus data.

ELVN valuation and analyst view

Trailing P/E-32.23
Trailing EPS-1.5729 USD
Price / book7.32
Dividend yield0.00%
Market cap3.83B
Analyst consensusBuy (8 buy / 0 hold / 0 sell)
Avg price target67.57 USD

Related research pages

Frequently asked questions

When is Enliven Therapeutics (ELVN)'s next earnings date?

Enliven Therapeutics is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.38 USD.

Did ELVN beat earnings last quarter?

In its 2026-05-07 report, ELVN posted EPS of -0.38 USD versus a -0.44 USD estimate — a beat of 13.6%.

What is ELVN's earnings track record?

Over the last 6 reported quarters with consensus data, ELVN beat estimates 4 times (67%).

What is ELVN's current P/E ratio and EPS?

ELVN trades at a trailing P/E of -32.23 on trailing EPS of -1.5728990467190682 USD.

What do analysts rate ELVN?

Analyst consensus is "Buy" across 8 ratings (0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 67.57 USD.